WO2015061507A1

WO2015061507A1 - Dithiolane functionalized nucleoside amidites and supports for stronger immobilization of bio-molecules on solid surfaces

Info

Publication number: WO2015061507A1
Application number: PCT/US2014/061850
Authority: WO
Inventors: Suresh C. Srivastava; Santhosh K. THATIKONDA; Sant K. SRIVASTAV; Praveen K. SHUKLA; Alok Srivastava
Original assignee: Chemgenes Corporation
Priority date: 2013-10-23
Filing date: 2014-10-22
Publication date: 2015-04-30
Also published as: CA2928190C; KR102325668B1; KR20160096596A; JP6463750B2; EP3060572A4; US9969764B2; US20170037076A1; CA2928190A1; JP2016537335A; EP3060572A1; CN105916872A

Abstract

This invention is related to nucleic acid chemistry and describes novel 1,2- dithiolane functionalized nucleoside phosphoramidites (1, Chart 1) and corresponding solid supports (2, Chart 1). In addition to these derivatives, 1,2- dithiolane moiety can also be functionalized to at the various positions of the nucleobase and sugar part as shown in Schemes 1 to 8. The nucleosides of our invention carry a primary hydroxyl for DMTr (4,4'-dimethoxytrityl) function for chain elongation. Furthermore, the phosphoramidite function is attached at the 3'- hydroxyl of the nucleoside. This allows oligonucleotide chain extension under standard DNA and RNA synthesis chemistry conditions and techniques, thus leading to high quality oligonucleotides. These derivatives are useful for introduction of reactive thiol groups either at 3'- or 5 '-end of the oligonucleotides on the solid supports such as gold, silver and quantum dots.

Description

PATENT COOPERATION TREATY APPLICATION

DITHIOLANE FUNCTIONALIZED NUCLEOSIDE AMIDITES AND SUPPORTS FOR STRONGER IMMOBILIZATION OF BIO-MOLECULES ON SOLID

SURFACES

CROSS REFERENCE TO RELATED APPLICATION

This Patent Cooperation Treaty Application is based on, and claims the benefit of U.S. Provisional Patent Application No. 61/894,872, filed October 23, 2013, which is incorporated herein by reference in its entirety.

FIELD OF THE INVENTION

This invention is related to nucleic acid chemistry and describes novel 1,2- dithiolane functionalized nucleoside phosphoramidites (1, Chart 1) and corresponding solid supports (2, Chart 1). These derivatives are useful for introduction of reactive thiol groups either at 3'- or 5 '-end of the oligonucleotides on the solid supports such as gold, silver and quantum dots. Further advantage of these probes is that they have relatively long linker arm, which allows clean formation of the monomers on the solid surfaces and keeps the self-assembled monomers in the optimum distance from the solid support. The nucleosides of our invention carry a primary hydroxyl for DMTr (4,4'-dimethoxytrityl) function for chain elongation. Furthermore, the phosphoramidite function is attached at the 3 '-hydroxyl of the nucleoside. This allows oligonucleotide chain extension under standard DNA and RNA synthesis chemistry conditions and techniques, thus leading to high quality oligonucleotides. Pairs of oligonucleotide-gold nanoparticle conjugates, due to dithiolane unit serve as unique probes for recognizing specific sequences in DNA segments, as building blocks for assembling novel structures, bio-diagnostics and nano technology based therapeutics. BACKGROUND OF THE INVENTION

In recent years, development of nanometer-sized structures has received much attention for various molecular biological applications. Gold is probably the most suited element because it exhibits a high chemical stability (noble metal), is characterized by its ability to strongly absorb the visible light at definite wavelengths and is intrinsically not toxic. The thiol (R-SH) modified oligonucleotides serve as attractive tools with a vast number of potential applications in the field of nucleic acid chemistry such as it enables covalent attachment of variety of ligands that contain (a) α,β-unsaturated ketone; (b) maleimide; (c) other Michael acceptor groups; or (d) cysteines in proteins to make disulfide bonds. In addition to this, thiol has a strong specific interaction with gold surface to form reversible covalent bond with gold.

The reactive thiol group can be introduced into oligonucleotides by incorporating sulfide-modified phosphoramidite monomers during oligonucleotide synthesis. Generally, two different types of sulfide modified monomers viz disulfide strategy [Jones, D. S., Hachmann, J. P., Conrad, M. J., Coutts, S., Livingston, D. A. US patent Number 5391785, 1995] or S-trityl protection [Connolly, B. A.; Rider, P. Nucleic Acids Res. 1985 13, 4485] are very popular to achieve this. Reactive thiol group from the disulfide is generated by treating oligonucleotides with reducing agent such as dithiothreitol (DTT). Whereas, in the other S-trityl strategy, it is generated by cleaving trityl group by silver nitrate. However, this strategy has clear disadvantage of elaborate cleavage process of trityl group with the silver nitrate, which results in relatively poor yields of the final oligonucleotide. Hence, disulfide modified phosphoramidites serve as superior probes for generating thiol groups. The most popular disulfide probes are with the general formula DMT-O-R-S-S-R-O- P(CE)(Nz^'Pr2), where R being C3 or C6 spacer arm [Jones, D. S., Hachmann, J. P., Conrad, M. J., Coutts, S., Livingston, D. A. U.S. patent Number 5391785, 1995]. Because of its interesting properties, we therefore carried out detailed investigation to develop a new synthetic and purification method which gives acyclic disulfide phosphoramidite (where R is C3 spacer) in a high purity for commercial, research and development. Our optimized synthetic protocol is reproducible, suitable for multi gram scale and yields target phosphoramidite in high purity by ³¹P NMR (>94%). [Srivastava, S. C; Thatikonda, S. K.; Srivastav, S. K. Shukla, P. U. S. Patent Application No. 2012/000103, 2012].

Nuzzo and Allara have discovered that reactive thiol group adsorb on gold surface and forms ordered mono layers. [Nuzzo, R. G., Allara, D. L. Jour. Am. Chem. Soc. 1983, 105, 4481]. After this, oligonucleotides with thiol group are very much used to generate self-assembled monolayers (SAMs) on the gold surfaces. Although different molecules can be immobilized (silanes, carboxylic acids, pyridines, sulphites and thiols) on different surfaces (gold, silver, platinum, copper, mercury and glass), chemisorption of thiols on gold is a common and simple procedure to immobilize probes on a surface. DNA functionalized gold nanoparticles have since become widely used building blocks in key nucleic acid based assembly strategies and serve as unique probes for recognizing specific sequences in DNA segments [Storhoff, J. J., Elghanian, R., Mucic, R. C, Mirkin, C. A., and Letsinger, R. L. J. Am. Chem. Soc. 1998 120, 1959] as a building blocks for assembling novel structures and materials [Mucic, R. C, Storhoff, J. J., Mirkin, C. A., Letsinger, R. L. J. Am. Chem. Soc. 1998 120, 12674] and bio diagnostics and nano technology based therapeutics [Merkins, C. A., Letsinger, R. L., Mucic, R. C, Storhoff, J. J. Nature, 1996, 382, 607; Hurst, S. J., Hill, H. D., Mirkin, C. A. J. Am. Chem. Soc. 2008, 130, 12192]. It's been proven that formation of these monolayers is influenced by several factors such as temperature, solvent, buffer concentration, chain length of the adsorbate, cleanliness of the substrate, and rate of reaction with the surface and the reversibility of adsorption of the components of the monolayer. These applications depend on the reversible association of gold and sulfur bond between the attached oligonucleotide and nano particle.

The oligonucleotides attached with single thiol group are unstable during the washing steps and formation of stable attachment of oligonucleotides is very important property for its success in applications such as for DNA chip technology. The covalent bond between gold and sulfur is in the order of magnitude from 30 to 40 Kcal/mol, which is relatively weak in order to anchor a biopolymer onto a surface. [Dubois L. H., Zegarski B. R., Nuzzo R. G. Proc. Nati. Acad. Sci. USA 1987 84 4739; Liepold, P., Kratzmuller, T., Persike, N., Bandilla, M., Hinz, M., Wieder, 15 H., Hillebrandt, H., Ferrer, E., Hartwich, G. Anal Bioanal Chem, 2008, 391, 1759-1772]. It has been reported that oligonucleotides that are conjugated with mono functional thiol group are slowly lost at higher temperatures and also in the presence of high salt concentration buffers [Li, Z., Jin, R., Mirkin, C. A., Letsinger, R. L. Nucleic Acids Res. 2002, 30, 1558]. The stability studies by Letsinger et. al. on SAMs of oligonucleotides that are conjugated to gold surface by mono thiol group revealed that these are completely displaced by treating with the buffers containing DTT [Letsinger, R. L., Elghanian, R., Viswanadham, G., Mirkin, C. A. Bioconj. Chem. 2000, 11, 289]. This feature limits applications of these probes in solutions containing thiols such as a PCR solution that has DTT as a stabilizer for the polymerase enzyme.

So there is strong need to develop novel disulfide compounds that are capable of forming stable SAMs of oligonucleotides for wider biological applications. One can anticipate that stability of mono layers could be increased by multiple numbers of gold-sulfur bonds per oligonucleotides. There have been few reports [Letsinger, R. L., Elghanian, R., Viswanadham, G., Mirkin, C. A. Bioconj. Chem. 2000, 11, 289-291; Hartwich, G., Frischmann, P., Ferrer, E., U.S. Pat. No. 7601848, 2002; Seliger, H., Prokein, T. U.S. Patent No 2005/0059728, 2004] that has introduced novel thiol modifiers which can generate multiple thiol groups per oligonucleotide. Its been proved that SAMs produced by these modifications are much more stable than corresponding SAMs generated by mono thiol modifier in buffers containing DTT [Letsinger, R. L., Elghanian, R., Viswanadham, G., Mirkin, C. A. Bioconj. Chem. 2000, 11, 289]. However the DMT group attached to the side chain in the disclosed art is attached to a secondary hydroxyl, which can effect the quality of oligonucleotides attached to solid surfaces. The present invention utilizes nucleoside 5'- DMT group for oligonucleotide growth band thereby synthesis of high quality dithiolane oligonucleotides. Chart 1: Chemical structures of N2-Guanosine (06-protected) functionalized dithiolane phosphoramidites 1, solid supports 2 and previously disclosed dithiolane phosphoramidites 3 and their solid supports 4.

Previously, we have described five membered disulfide (dithiolane) based anchoring group 3 (Chart 1) for the introduction of two thiol groups [Srivastava, S. C, Thatikondra, S. K., Srivastav, S. K., Shukla, P.K., Srivastava, A., U.S. Provisional Application is 61/795851, filed October 27, 2012; U.S. Non-Provisional Application 14/065,385, filed October 28, 2013.]. This dithiolane modification offered primary hydroxyl group to attach DMT group for the purpose of oligonucleotide synthesis, offers high quality oligonucleotide, and can potentially afford gold-oligonucleotide conjugates that exhibit greater stability.

References:

Cao, H., Yong, J., Yinsheng W. Jour, of the Am. Chem. Soc. 2007, 129, 12123-12130. Connolly, B. A., Rider, P. Nucleic Acids Res. 1985 13, 4485

Dubois L. H., Zegarski B. R., Nuzzo R. G. Proc. Nati. Acad. Sci. USA 1987 84 4739- 4742.

Hartwich, G., Frischmann, P., Ferrer, E., U.S. pat. No. 7601848, filed Dec 21, 2002.

Hurst, S. J., Hill, H. D., Mirkin, C. A. J. Am. Chem. Soc. 2008, 130, 12192.

Jones, D. S., Hachmann, J. P., Conrad, M. J., Coutts, S., Livingston, D. A. US patent Number 5391785, Date filed Feb 21, 1995.

Letsinger, R. L., Elghanian, R., Viswanadham, G., Mirkin, C. A. Bioconj. Chem. 2000, 11, 15 289-291.

Li, Z., Jin, R., Mirkin, C. A., Letsinger, R. L. Nucleic Acids Res. 2002, 30, 1558-62.

Liepold, P., Kratzmuller, T., Persike, N., Bandilla, M., Hinz, M., Wieder, H., Hillebrandt, H., Ferrer, E., Hartwich, G. Anal Bio anal Chem, 2008, 391, 1759-1772.

Merkins, C. A., Letsinger, R. L., Mucic, R. C, Storhoff, J. J. Nature, 1996, 382, 607. 20.

Mucic, R. C, Storhoff, J. J., Mirkin, C. A., Letsinger, R. L. J. Am. Chem. Soc. 1998 120, 12674-12675.

Nuzzo, R. G., Allara, D. L. Jour. Am. Chem. Soc. 1983, 105, 4481.

Seliger, H., Prokein, T. U.S. Patent No 2005/0059728 Al, filed Aug 26, 2004 25.

Srivastava, S. C; Thatikonda, S. K.; Srivastav, S. K. Shukla, P. U. S. Patent

Application No. 2012/000103, 2012.

Srivastava, S. C, Thatikonda, S. K., Srivastav, S., Srivastava, A. The Serial No. for the provisional application is 61/795851, its filing date is October 27, 2012.

Storhoff, J. J., Elghanian, R., Mucic, R. C, Mirkin, C. A., and Letsinger, R. L. J. Am. Chem. Soc. 1998 120, 1959-1964. SUMMARY OF INVENTION

A phosphoramidite derivative of structure 1 and solid support of structure 2

Structure 1 Structure 2

A C5 -dithiolane functionalized pyrimidine nucleoside as described structure 3, 4.

Structure 3 Structure 4

A C8- dithiolane functionalized purine nucleoside as described in the structure

Structure 5 Structure 6 A 2'-0-dithiolane functionalized pyrimidine nucleoside as described in the structure 7, 8.

Structure 7 Structure 8

A 2'-0-dithiolane functionalized purine nucleoside as described structure 9, 10.

Structure 9 Structure 10

A C5-Dithiolane functionalized pyrimidine nucleoside amidites as described in the structure 11, 12.

Structure 11 Structure 12 A C8-dithiolane functionalized purine nucleoside amidites as described in the structure 13, 14.

Structure 13 Structure 14

A 2'-0-dithiolane functionalized pyrimidine nucleoside amidites as described in the structure 15, 16.

Structure 15 Structure 16

A 2'-0-dithiolane functionalized purine nucleoside amidites as described in the structure 17, 18.

¾s;wset i

Structure 17 Structure 18 A C-5 functionalized pyrimidine and C8-functionalized purine succinates as shown in the structure 19-22

= i-i-d&c&ss-e ;:; ·:·: =·::!-·: 5·· j :;:s ·.*".=·; are : : ^::i≤^■ w ·::^■- :·. :_;: r-.:^:s- -2 - ~s :- . :J^:".-=s ε

A 2'-0-functionalized pyrimidine and purine succinates as shown structure 23-26.

rt = 1-20 csi i^ atoms A C5 functionalized pyrimidine and purine solid supports as shown structure 27-30.

An oligoribonucleotide or an oligodeoxyribonucleotide containing with C5 and 2'-0-dithiolane functionalized Structure 1 to Structure 30 as described above.

A conjugate of the oligoribonucleotide or the oligodeoxyribonucleotide from as described above with solid supports such as gold, quantum dots as illustrated in the figure below.

The thiol modified oligonucleotides have vast number of applications in the field of nucleic acid chemistry such as it enables covalent attachment of a variety of ligands and also has an ability to form relatively stronger bond with gold surface. Hence, oligonucleotides with thiol groups can chemisorb onto gold surface and generate self-assembled mono layers (SAMs). DNA functionalized gold nanoparticles have become widely used building blocks in key nucleic acid based assembly strategies and serve as unique probes for recognizing specific sequences in DNA segments, as building blocks for assembling novel structures and materials, bio diagnostics and nano technology based therapeutics.

Even though thiol group forms relatively stronger bond with elemental gold (about 30-40 Kcal/mole), it gets displaced at higher temperature, in high salt concentration buffers and in presence other thiols. For many of applications with these conjugates strong binding of the oligonucleotides to the gold nano particles is required. However to circumvent displacement of thiol, a few cyclic disulfide modifiers that can introduce multiple thiol groups have been introduced in the prior art. Their stability studies revealed that these multi-thiol functionalized oligonucleotides form relatively more stable SAMs compared to the corresponding mono-thiol derivatives.

In the present invention, we describe the design and efficient synthesis of cyclic dithiolane functionalized phosphoramidite derivative 1 (Chart 1) and corresponding dithiolane succinyl solid supports 2 (Chart 1). Previously we have described five membered disulfide (dithiolane) based anchoring group 3 and 4 (Chart 1) for the introduction of two thiol groups [Srivastava, S. C, Thatikonda, S. K., Srivastav, S. K., Shukla, P. K. Srivastava, A. U.S. Provisional Application is 61/795851, filed October 27, 2012; U.S. Non-Provisional Application 14/065,385, filed October 28, 2013]. This dithiolane modification is simple to synthesize, is broadly useful, and can potentially afford gold-oligonucleotide conjugates that exhibit greater stability. The task of the present invention is to extend this dithiolane technology further into nucleosides. In addition to the synthesized dithiolane functionalized derivatives 1 (Chart 1), we envisioned various other functionalized derivatives compounds from Schemes 1 to 8. Conjugation of dithiolane moiety to the either nucleobase or to sugar part with linker arm should generate very interesting functionalized thiol oligonucleotides. The advantage of relatively long linker arm is that it allows clean formation of the monomers on the solid surfaces and keeps the self-assembled monomers in the optimum distance from the solid support. Pairs of oligonucleotide-gold nano-particle conjugates serve as unique probes for recognizing specific sequences in DNA segments, as building blocks for assembling novel structures, bio diagnostics and nano technology based therapeutics.

BRIEF DESCRIPTION OF DRAWINGS

Figure 1: HPLC purity analysis of the 2-(12-Aminododecanyl)-2'-deoxy-5'-O-(4,4'- Dimethoxytrityl)-06-(2-trimethylsilylethyl)-Guanosine (54). Analytical purity of compounds was checked using a Varian Prostar HPLC equipped with ChromSep SS column (4.6 X 250 mm) 10 and ChromSep Guard-Column OmniSpher 5 CI 8. Mobile phase: A 0.1M Triethylammonium acetate (TEAA); B is CH3CN. Analysis was performed with the linear gradient of increase of B from 65 to 98% in 20 min. Peaks were detected by UV absorption at 254 nm.

Figure 2: HPLC table peaks of the 2-(12-Aminododecanyl)-2'-deoxy-5'-O-(4,4'- Dimethoxytrityl)-06-(2-trimethylsilylethyl)-Guanosine (54) .

Figure 3: ESI/MS spectra of the 2-(12-Aminododecanyl)-2'-deoxy-5'-O-(4,4'- Dimethoxytrityl)-06-(2-trimethylsilylethyl)-Guanosine (54). MS mlz (C-igHegNeOeSi) [M -H]^~ 852.4, calcd 853.18. ESI/MS analysis was carried on Perkin Elmer 30 PE- SCIEX API-150 mass spectrometer.

Figure 4: 1H NMR of 2-(12-Aminododecanyl)-2'-deoxy-5'-O-(4,4'-dimethoxytrityl)- O6-(2-trimethylsilylethyl)-Guanosine (54). 1H NMR was recorded on

[0001.]Bruker 500 MHz NMR spectrophotometer. Chemical shifts are calibrated with deuterated solvent CDC13 (δ 7.26 ppm).

Figure 5: HPLC purity analysis of the 2'-Deoxy-5'-O-(4,4'-Dimethoxytrityl)-2-(12- (5-(l,2-dithiolan-3-yl)pentanamide)-dodecyl)-O6-(2-trimethylsilylethyl)-Guanosine (55). Analytical purity of compounds was checked using a Varian Prostar HPLC equipped with ChromSep SS column (4.6 X 250 mm) 10 and ChromSep Guard- Column OmniSpher CI 8. Mobile phase: A 0.1M Triethylammonium acetate (TEAA); B is CH3CN. Analysis was performed with the linear gradient of increase of B from 0 to 50% in 20 min. Peaks were detected by UV absorption at 254 nm.

Figure 6: HPLC table peaks of the 2'-Deoxy-5'-0-(4,4'-Dimethoxytrityl)-2-(12-(5-

(l,2-dithiolan-3-yl)pentanamide)-dodecyl)-O6-(2-trimethylsilylethyl)-Guanosine

(55).

Figure 7: ESI/MS spectra of the 2'-Deoxy-5'-O-(4,4'-Dimethoxytrityl)-2-(12-(5-(l,2- dithiolan-3-yl)pentanamide)-dodecyl)-O6-(2-trimethylsilylethyl)-Guanosine (55). MS mlz CsgH_fjoNgOvSzSi ([M + H]⁺ 1042.2, calcd 1041.18). ESI/MS analysis was carried on Perkin Elmer 30 PE-SCIEX API- 150 mass spectrometer.

Figure 8: 1H NMR of 2^*-Deoxy-5'-O-(4,4^*-Dimethoxytrityl)-2-(12-(5-(l,2-dithiolan- 3-yl)pentanamide)-dodecyl)-06-(2-trimethylsilylethyl)-Guanosine (55). 1H NMR was recorded on Bruker 500 MHz NMR spectrophotometer. Chemical shifts are calibrated with deuterated solvent CDC13 (δ 7.26 ppm).

Figure 9: HPLC purity analysis of the 3'-(2-Cyanoethyl diisopropylphosphoramidite)-2'-deoxy-5'-O-(4,4'-dimethoxytrityl)-2-(12-(5-(l,2- dithiolan-3-yl)pentanamide)-dodecyl)-O6-(2-trimethylsilylethyl)-Guanosine (1). Analytical purity of compounds was checked using a Varian Prostar HPLC equipped with ChromSep SS column (4.6 X 250 mm) 10 and ChromSep Guard-Column OmniSpher C18. Mobile phase: A 0.1M Triethylammonium acetate (TEAA); B is CH3CN. Analysis was performed with the linear gradient of increase of B from 0- 30% in 20 min. Peaks were detected by UV absorption at 254 nm.

Figure 10: HPLC table peaks of the 3'-(2-Cyanoethyl diisopropylphosphoramidite)- 2'-deoxy-5'-O-(4,4'-dimethoxytrityl)-2-(12-(5-(l,2-dithiolan-3-yl)pentanamide)- dodecyl)-06-(2-trimethylsilylethyl)-Guanosine (1). Figure 11: ESI/MS spectra of the 3'-(2-Cyanoethyl diisopropylphosphoramidite)-2'- deoxy-5'-O-(4,4'-dimethoxytrityl)-2-(12-(5-(l,2-dithiolan-3-yl)pentanamide)- dodecyl)-06-(2-trimethylsilylethyl)-Guanosine (1). MS mlz C₆₅H₉₇N₈O₈PS₂S1

[0002.] ([M + H]⁺ 1242.3, calcd 1241.58). ESI/MS analysis was carried on Perkin Elmer 30 PE-SCIEX API-150 mass spectrometer.

Figure 12: ³¹P NMR spectra of 3'-(2-Cyanoethyl diisopropylphosphoramidite)-2'- deoxy-5'-O-(4,4'-dimethoxytrityl)-2-(12-(5-(l,2-dithiolan-3-yl)pentanamide)- dodecyl)-O6-(2-trimethylsilylethyl)-Guanosine (1). ³¹P NMR was recorded on Bruker 202 MHz NMR spectrophotometer. Solvent used for NMR analysis was CDCI₃.

Figure 13: UV absorption spectra of 3'-(2-Cyanoethyl diisopropylphosphoramidite)- 2'-deoxy-5'-O-(4,4'-dimethoxytrityl)-2-(12-(5-(l,2-dithiolan-3-yl)pentanamide)- dodecyl)-06-(2-trimethylsilylethyl)-Guanosine (1). UV absorption spectrum was recorded on Cary 50 Bio UV -Visible spectrophotometer in the range of 320 to 240 nm.

DETAILED DESCRIPTION OF THE INVENTION

The present invention further extends this dithiolane technology further into nucleosides. Conjugation of dithiolane moiety to the either nucleobase or to sugar part with linker arm should generate very interesting functionalized thiol oligonucleotides. The advantage of relatively long linker arm is that it allows clean formation of the monomers on the solid surfaces and keeps the self-assembled monomers in the optimum distance from the solid support. Pairs of oligonucleotide-gold nano-particle conjugates serve as unique probes for recognizing specific sequences in DNA segments, as building blocks for assembling novel structures, bio diagnostics and nano technology based therapeutics.

One embodiment of the invention is directed to a nucleoside, comprising: a guanine, a 2'-deoxyribose, a dithiolane derivative at N2 of the guanine; and a phosphoramidite derivative at the 3'-0 of the deoxyribose, or a solid support at the 3'-0 of the deoxyribose, wherein the nucleoside is represented by Structure 1 or Structure 2:

Structure 1 Structure 2

One embodiment of the invention is directed to a nucleoside, comprising: a pyrimidine; a ribose; and a dithiolane derivative at C5 of the pyrimidine, wherein the nucleoside is represented by Structure 3 or Structure 4:

Structure 3 Structure 4

One embodiment of the invention is directed to a nucleoside, comprising: a purine; a ribose; and a dithiolane derivative at C8 of the purine, wherein the nucleoside is represented by Structure 5 or Structure 6: ¾Ί

Structure 5 Structure 6

One embodiment of the invention is directed to a nucleoside, comprising: a pyrimidine; a ribose; and a dithiolane derivative at 2'-0 of the ribose, wherein the nucleoside is represented by Structure 7 or Structure 8:

Structure 7 Structure 8

One embodiment of the invention is directed to a nucleoside, comprising: a purine; a ribose; and a dithiolane derivative at 2Ό of the ribose, wherein the nucleoside is represented by Structure 9 or Structure 10:

Structure 9 Structure 10 One embodiment of the invention is directed to a nucleoside, comprising: a pyrimidine; a ribose; a dithiolane derivative at C5 of the pyrimidine; and a phosphoramidite group at 3'-0 of the ribose, wherein the nucleoside is represented by Structure 11 or Structure 12:

Structure 11 Structure 12

One embodiment of the invention is directed to a nucleoside, comprising: a purine; a ribose; a dithiolane derivative at C 8 of the purine; and a phosphoramidite group at 3'-0 of the ribose, wherein the nucleoside is represented by Structure 13 or Structure 14:

Structure 13 Structure 14

One embodiment of the invention is directed to a nucleoside, comprising: a pyrimidine; a ribose; a dithiolane derivative at 2'-0 of the ribose; and a phosphoramidite group at 3'-0 of the ribose, wherein the nucleoside is represented by Structure 15 or Structure 16:

Structure 15 Structure 16

One embodiment of the invention is directed to a nucleoside, comprising: a purine; a ribose; a dithiolane derivative at 2'-0 of the ribose; and a phosphoramidite group at 3'-0 of the ribose, wherein the nucleoside is represented by Structure 17 or Structure 18:

Structure 17 Structure 18

One embodiment of the invention is directed to a nucleoside, comprising: a ribose; a succinate group at 3'-0 of the ribose; and a pyrimidine or a purine, wherein the pyrimidine has a dithiolane derivative at C5 and the pyrimidine is represented by Structure 19 or Structure 20, the purine has a dithiolane derive at C8 and is represented by Structure 21 or Structure 22:

One embodiment of the invention is directed to a nucleoside, comprising: a nucleobase; a ribose; a dithiolane derivative at 2'-0 of the ribose; and a succinate group at 3'-0 of the ribose, wherein the nucleobase is a pyrimidine as represented by Structure 23 or Structure 24, or a purine as represented by Structure 25 or Structure 26:

One embodiment of the invention is directed to a nucleoside, comprising: a nucleobase; a ribose; a dithiolane derivative at 2'-0 of the ribose; and a solid support at 3Ό- of the ribose, wherein the nucleobase is a pyrimidine as represented by Structure 27 or Structure 28, and a purine as represented by Structure 29 or Structure 30:

One embodiment of the invention is directed to a nucleoside, comprising a dithiolane derivative according to one of the above-mentioned nucleosides, wherein the nucleoside is represented by one of Structure 1 through Structure 30.

One embodiment of the invention is directed to a conjugate, comprising: the nucleoside mentioned above, and a solid support, wherein the solid support is gold or quantum, and the conjugate is presented by the figure below:

To show this, we have successfully synthesized N2-functionalized deoxy- guanosine amidites (1, Chart 1) and proposed the scheme for the corresponding compound with solid support (2, Chart 1). In addition to these we proposed various dithiolane functionalized DNA and RNA amidites and solid supports (Schemes 1 to 8). These monomers are useful in generating the thiol functionalities at 3'- or 5 '-end of oligonucleotides. With these improvements, we strongly believe that our probes are designed to be ideally suited to application in high quality probes consisting of dithiolane moieties.

The thiol modified oligonucleotides have vast number of applications in the field of nucleic acid chemistry such as it enables covalent attachment of a variety of ligands and also has an ability to form relatively stronger bond with gold surface. DNA functionalized gold nanoparticles have become widely used building blocks in key nucleic acid based assembly strategies and therapeutics. Even though thiol group forms relatively stronger bond with elemental gold (about 30-40 Kcal/mole), it gets displaced at higher temperature, in high salt concentration buffers and in presence other thiols. For many of applications with these conjugates strong binding of the oligonucleotides to the gold nano particles is required. However to circumvent displacement of thiol, a few cyclic disulfide modifiers that can introduce multiple thiol groups have been introduced in the 15 prior art. Their stability studies revealed that these multi-thiol functionalized oligonucleotides form relatively more stable SAMs compared to the corresponding mono-thiol derivatives. In the present application, we describe the design and efficient synthesis of N2 cyclic dithiolane functionalized phosphoramidite derivative 1 (Chart 1) and proposed synthesis of corresponding dithiolane succinyl CPG supports 2 (Chart 1). In addition to the synthesized dithiolane functionalized derivatives 1 (Chart 1), we envision various other functionalized derivatives compounds from Schemes 1 to 8. Conjugation of dithiolane moiety to the either nucleobase or to sugar part with linker arm should generate very interesting functionalized thiol oligonucleotides. The advantage of relatively long linker arm is that it allows clean formation of the monomers on the solid surfaces and keeps the self-assembled monomers in the optimum distance from the solid support. Pairs of oligonucleotide-gold nano-particle conjugates serve as unique probes for recognizing specific sequences in DNA segments, as building blocks for assembling novel structures, bio diagnostics and nano technology based therapeutics.

2-Fluoro of the nucleoside 53 [Cao, H., Yong, J., Yinsheng W. Jour, of the Am. Chem. Soc. 2007, 129, 12123-12130] was displaced by the 1, 12- diaminododecane to afford amino nucleoside 54 in 79% yield. Nucleoside 54 was coupled to thioctic acid using EDC.HC1 to get N2-dithiolane coupled product 55. Finally, compound 55 was converted to target amidite 1 using N,N- (diisopropyl)phosphoramidochloridite reagent and N, N'-diisopropylethylamine in anhydrous THF in 67% yield (Scheme 9). Compound 55 can also be converted to corresponding succinate 57 (Scheme 10) followed by coupling to the suitable solid support to get compound 2 (Scheme 10). These target compounds 1 and 2 can be incorporated into the oligonucleotide sequence to get the dithiolane modification at the either 3'- or 5 '-end of the oligonucleotide sequence as depicted in Schemes 9 and 10. Scheme 1: Synthetic scheme for C5 -dithiolane functionalized Uridine amidites and supports.

Reagents and Conditions: (a) Corresponding diamine, MeOH; (b) Thioctic acid, EDC.HC1, N,AT-dimethylformamide, rt; (c) 2-Cyanoethyl N V- (diisopropyl)phosphoramidochloridite, N,N'-diisopropylethylamine, anhydrous THF; (d) Succinic-anhydride, 4-dimethylaminopyridine, anhydrous pyridine; (e) HBTU, N,N'-diisopropylethylamine, Solid support with amine functionality.

The proposed Scheme 1 outlines synthesis of uridine C-5 spacer moiety, at the terminal of which dithiolane function is attached. Other modification of solid chain at C-5 can be envisioned such as introduction of alkyl carboxy function for further elongation of C-5 and eventually attaching dithiolane function. Besides 2'- deoxy nucleosides 2'- modified nucleosides are also envisioned , such as 2'-F, 2'-Omethyl, 2'-0 alkyl, 2'- O-amino (protected). Various chromophores can be attached to this nucleoside as well as tho oligonucleotide chain for better and diverse detection applications. Phosphoramidites and succinates are envisioned. The later function can be utilized to attach the compound (9) to various solid support.

Scheme 2: Synthetic scheme for C5-dithiolane functionalized Cytidine amidite and supports

« 16

Reagents and Conditions: a) Corresponding diamine, MeOH; b) Thioctic acid, EDC.HCl, N,N'-dimethylformamide, rt; c) 2-Cyanoethyl Ν,Ν¹- (diisopropyl)phosphoramidochloridite, N,N'-diisopropylethylamine, anhydrous THF; d) Succinic-anhydride, 4-dimethylaminopyridine, anhydrous pyridine; e) HBTU, N,N'-diisopropylethylamine, Solid support with amine functionality.

The proposed Scheme 2 outlines synthesis of cytidine C-5 spacer moiety, at the terminal of which dithiolane function is attached. Other modification of solid chain at C-5 can be envisioned such as introduction of alkyl carboxy function for further elongation of C-5 and eventually attaching dithiolane function. Besides 2'- deoxy nucleosides 2'- modified nucleosides are also envisioned , such as 2'-F, 2'- Omethyl, 2'-0 alkyl, 2'- O-amino (protected). Various chromophores can be attached to this nucleoside as well as to oligonucleotide chain for better and diverse detection applications. Phosphoramidites and succinates are envisioned. The later function can be utilized to attach the compound (15) to various solid support

Scheme 3: Synthetic scheme for C8-dithiolane functionalized Adenosine amidite and supports

Reagents and Conditions: a) Corresponding diamine, MeOH; b) Thioctic acid, EDC.HC1, N,N'-dimethylformamide, rt; c) 2-Cyanoethyl Ν,Ν¹- (diisopropyl)phosphoramidochloridite, N,N'-diisopropylethylamine, anhydrous THF; d) Succinic-anhydride, 4-dimethylaminopyridine, anhydrous pyridine; e) HBTU, N,N'-diisopropylethylamine, Solid support with amine functionality.

The proposed Scheme 3 outlines synthesis of deoxy adenosine C-8 spacer moiety, at the terminal of which dithiolane function is attached. Other modification of solid chain at C-8 can be envisioned such as introduction of C-8- O-alkyl function for further elongation of C-8 and eventually attaching dithiolane function. Besides 2'- deoxy nucleosides 2'- modified nucleosides are also envisioned, such as 2'-F, 2'- Omethyl, 2'-0 alkyl, 2'- O-amino (protected). Various chromophores can be attached to this nucleoside as well as to oligonucleotide chain for better and diverse detection applications. Phosphoramidites and succinates are envisioned. The later function can be utilized to attach the compound (21) to various solid support.

Scheme 4: Synthetic scheme for C8-dithiolane functionalized Guanosine amidite and supports.

Reagents and Conditions: a) Corresponding diamine, MeOH; b) Thioctic acid, EDC.HC1, N,N'-dimethylformamide, rt; c) 2-Cyanoethyl Ν,Ν¹- (diisopropyl)phosphoramidochloridite, N,N'-diisopropylethylamine, anhydrous THF; d) Succinic-anhydride, 4-dimethylaminopyridine, anhydrous pyridine; e) HBTU, N,N'-diisopropylethylamine, Solid support with amine functionality. The proposed Scheme 4 outlines synthesis of guanosine C-8 spacer moiety, at the terminal of which dithiolane function is attached. Other modification of solid chain at C-8 can be envisioned such as introduction of 8-O-alkyl function for further elongation of C-8 and eventually attaching dithiolane function. Besides 2'- deoxy nucleosides, 2'- modified nucleosides are also envisioned, such as 2'-F, 2'-Omethyl, 2'-0 alkyl, 2'- O-amino (protected). Various chromophores can be attached to this nucleoside as well as to oligonucleotide chain for better and diverse detection applications. Phosphoramidites and succinates are envisioned. The later function can be utilized to attach the compound (27) to various solid support. In the proposed Scheme 4, 06 has been protected with a protecting group, which can be removed under mild conditions to generate free 06 carbonyl function of guanosine.

Scheme 5: Synthetic scheme for 2'-0-dithiolane functionalized Uridine amidite and supports.

34 Reagents and Conditions: a); b) Thioctic acid, EDC.HC1, N,AT-dimethylformamide, rt; c) 2-Cyanoethyl N,A/ -(diisopropyl)phosphoramidochloridite, Ν,Ν'- diisopropylethylamine, anhydrous THF; d) Succinic-anhydride, 4- dimethylaminopyridine, anhydrous pyridine; e) HBTU, N,N'-diisopropylethylamine, Solid support with amine functionality.

The proposed Scheme 5 outlines synthesis of uridine 2'-0-alkyl spacer moiety, at the terminal of which dithiolane function is attached. Other modification of solid chain at 2'-0- can be envisioned such as introduction of alkyl carboxy function for further elongation of 0-2'- and eventually attaching dithiolane function. Various chromophores can be attached to this nucleoside to synthesize oligonucleotide chains for better and diverse detection applications. Phosphoramidites and succinates are envisioned. The later function can be utilized to attach the compound (33) to various solid support.

Scheme 6: Synthetic scheme for 2'-0-dithiolane functionalized Cytidine amidite and supports.

Reagents and Conditions: a); b) Thioctic acid, EDC.HC1, N,AT-dimethylformamide, rt; c) 2-Cyanoethyl N,A/ -(diisopropyl)phosphoramidochloridite, Ν,Ν'- diisopropylethylamine, anhydrous THF; d) Succinic-anhydride, 4- dimethylaminopyridine, anhydrous pyridine; e) HBTU, N,N'-diisopropylethylamine, Solid support with amine functionality.

The proposed Scheme 6 outlines synthesis of cytidine 2'-0-alkyl spacer moiety, at the terminal of which dithiolane function is attached. Other modification of side chain at 2'-0- can be envisioned such as introduction of 2'-0- alkyl carboxy function for further elongation of 0-2'- and eventually attaching dithiolane function. Various chromophores can be attached to this nucleoside to synthesize oligonucleotide chains for better and diverse detection applications. Phosphoramidites and succinates are envisioned. The later function can be utilized to attach the compound (39) to various solid support.

Scheme 7: Synthetic scheme for 2'-0-dithiolane functionalized Adenosine amidite and supports.

The proposed Scheme 7 outlines synthesis of adenosine 2'-0-alkyl spacer moiety, at the terminal of which dithiolane function is attached. Other modification of side chain at 2'-0- can be envisioned such as introduction of 2'-0- alkyl carboxy function for further elongation of 0-2'- and eventually attaching dithiolane function. Various chromophores can be attached to this nucleoside to synthesize oligonucleotide chains for better and diverse detection applications. Phosphoramidites and succinates are envisioned. The later function can be utilized to attach the compound (45) to various solid support.

Scheme 8: Synthetic scheme for 2'-0-dithiolane functionalized Guanosine amidite and supports.

The proposed Scheme 8 outlines synthesis of guanosine 2'-0-alkyl spacer moiety, at the terminal of which dithiolane function is attached. Other modification of side chain at 2'-0- can be envisioned such as introduction of 2'-0- alkyl carboxy function for further elongation of 0-2'- and eventually attaching dithiolane function. Various chromophores can be attached to this nucleoside to synthesize oligonucleotide chains for better and diverse detection applications. Phosphoramidites and succinates are envisioned. The later function can be utilized to attach the compound (51) to various solid support.

In the proposed Scheme 8, 06 has been protected with a protecting group, which can be removed under mild conditions to generate free 06 carbonyl function of guanosine.

Scheme 9: Synthesis of N2-guanosine functionalized dithiolane

phosphoramidite and the corresponding oligonucleotides.

Reagents and Conditions: a) 1,12-diaminododecane in MeOH, 40 °C, 18 h, 79%; b) Thioctic acid, EDC.HCl, N,AT-dimethylformamide, rt, 67%; c) 2-Cyanoethyl Ν,Ν'- (diisopropyl)phosphoramidochloridite, N,N'-diisopropylethylamine, anhydrous THF, 0 C to rt, 66%>; d) Oligonucleotide synthesis;

Scheme 10: Synthesis of N2-guanosine functionalized dithiolane

solid supports and subsequent synthesis of oligonuceotides.

Reagents and Conditions: a) Succinicanhydride, 4-dimethylaminopyridine, anhydrous pyridine; b) HBTU, N,N'-diisopropylethylamine, CPG-long chain alkyl amine spacer.

Oligonucleotides such as 56 and 58 can be synthesized having different nucleosides of interest within sequence. B can be natural or modified nucleosides, purine or pyrimidine modifications, such as but not limited to, 5- Fluoro-U, 5-Fluoro dU, 5-fluoro-dC, 5-Fluro-rC, pseudouridine, 5-methyl-dU, 5-methyl-rU, 5-methyl-dC, 5-methyl-rC, 5-bromo-dU, 5-bromo-rU, 5-bromo-dC, 5-bromo-rC, 5-iodo-dU, 5- iodo-rU, 5-vinyl-dU, 5-vinyl-rU, 5 -vinyl thymidine, N-3 methyldeoxy uridine, N-3 methyl-ribouridine, N-3 methyl thymidine, 4-thio uridine, 4-thio-2'-deoxyuridine, 2,6-diaminopurine deoxy riboside, N-3 methyl ribothymidine, 2, 6-diaminopurine riboside, 8-bromo 2'- deoxy adenosine, 8-bromo-r-adenosine, 8-oxo-deoxy adenosine, 8-oxo-riboadenosine, 8-oxo-2'-deoxy- adenosine, 8-oxo-riboadenosine, 8-oxo-deoxy inosine, 8-oxo-ribo inosine, 8-bromo-deoxy inosine, 8-bromo-ribo-inosine, N-l methyl-riboadenosine, N-l methyl-2'- deoxy adenosine, N-l methyl 2'-deoxy inosine, N-l methyl riboadenosine, N-l methyldeoxy guanosine, N-l -methyl- riboguanosine, etheno adenosine, etheno 2'- deoxy adenosine, purine 2'- deoxy riboside, purine- ribonucleoside, 2-aminopurine-2 ' -deoxyriboside, 2-aminopurine-ribonucleoside. Labelling of internal positions of a DNA synthesized by this method is achievable with chromophores such as, but not limited to Fluoroscein-C-5 dT, Dabcyl- C-5 thymidine, internal carboxyl group 5-dU-methylacrylate, biotin dT ( biotin attached via spacer to C-5 of dU), amino-dT ( terminal amino attached via C-6 spacer to C-5 dU). The sugar modification of modified nucleosides could consist of 2'- deoxy-2 '- fluoro ribo nucleosides (2'-F-ANAs) such as A, C, G, U , Inosine and modified nucleosides containing 2'- Fluoro, in one or more positions of an RNA or DNA sequence synthesized by the method of this invention.

The sugar modification of modified nucleosides could consist of 2'- deoxy-2 '- methoxy ribo nucleosides (2'-OMe-) such as A, C, G, U, Inosine and modified nucleosides containing 2'- methoxy, in one or more positions of an RNA or DNA sequence synthesized by this method. The sugar modification of modified nucleosides could consist of 2'- deoxy-2' -amino ribo nucleosides (2'-NH2) such as A, C, G, U , Inosine and modified nucleosides containing 2'- amino, in one or more positions of an RNA or DNA sequence synthesized by this method. The sugar modification of modified nucleosides could consist of 2'- deoxy-2 '-terminal amino ribo nucleosides (2'-terminal NH2), attached via spacer from 2-10 atoms on nucleosides such as A, C, G, U, Inosine and modified nucleosides containing 2'- terminal amino, in one or more positions of an RNA or DNA sequence synthesized by this method. The sugar modification of modified nucleosides could consist of 2'- deoxy-2 '-methoxy ethoxy ribo nucleosides (2'-MOE), such as A, C, G, U, Inosine and modified nucleosides containing 2'- MOE, in one or more positions of an RNA or DNA sequence synthesized by this method. The sugar modification of modified nucleosides could consist of other 2'- O-alkyl groups, such as 2'- deoxy-2 '-ethoxy, propargyl, butyne ribo nucleosides (2'-OEt, O-Propargyl, 2'-0-Butyne), such as A, C, G, U , Inosine and modified nucleosides containing 2'- 2'-OEt, O-Propargyl, 2'-0-Butyne, in one or more positions of an RNA or DNA sequence synthesized by this method. EXAMPLE 1

2-(12-Aminododecanyl)-2'-deoxy-5'-0-(4,4^,-Dimethoxytrityl)-06-(2- trimethylsilylethyl)-Guanosine (54)

2-Fluoro-2'-deoxy guanosine nucleoside (5 g, 7.9 mmol) was dissolved in freshly prepared 1,12-diaminododecane in MeOH (79 mmol, 10:90, v/v). After stirring the reaction mixture at 40 °C for 18 hr it was evaporated to dryness and purified by silica gel column chromatography using CHCi₃:Triethylamine:MeOH (95:5:0 to 91 :5:4, v/v/v) to afford the compound 54 (5 gr, 79%) as white solid material R = 0.5

(Chloroform:methanol:TEA;90:05:05) MS m/z ([M + H]⁺ 854.2, calcd 853.18), MS m/z (C₄8H₆₈N₆0₆Si) [M -H]^~ 852.4, calcd 853.18); 1H NMR (DMSO,d⁶) 7.91 (s, 1 H), 7.32-7031 (d, 2H), 7.22-7.15 (m, 7H), 6.80-6.74 (m, 5H), 6.25-6.22 (t, 1H), 4.51 (s, 2H), 4.42 (s, 1H), 3.94-3.91 (q, 1H), 3.71-3.70 (d, 6H), 3.28-2.83 (m, 13H), 2.42-2.39 (q, 1H), 2.29-2.26(q, 1H),1.46 (s, 2H), 1.31-0.91(m, 23H), HPLC analysis single peak at 11.257 min (65 to 98% acetonitrile in 0.1M TEAA buffer) and purity is 98.54%.

EXAMPLE 2

2^,-Deoxy-5'-0-(4,4'-Dimethoxytrityl)-2-(12-(5-(l,2-dithiolan-3-yl)pentanamide)- dodecyl)-06-(2-trimethylsilylethyl)-Guanosine (55)

The compound 54 (2.5 g, 2.93 mmol) was dissolved in anhydrous Ν,Ν'- dimethylformamide (25 mL) and EDC.HCL (3.1 g, 16.11 mmol) was added to this. After stirring the reaction for 30 min, thioctic acid (3.02 g, 14.65 mmol) was added at room temperature. After stirring the reaction for 16 h at room temperature, it was evaporated to dryness and purified by silica gel column chromatography (CHCl₃:Hexane:Acetone:Triethylamine:MeOH, 47:30:20: 1 :2, v/v/v/v/v) to afford the compound 55 (2.4 g, 67%>) as white solid material. Rf = 0.6 (CHCl₃:Hexane:Acetone:Triethylamine:MeOH, 47:30:20: 1 :2, v/v/v/v/v);MS m/z

([M + H]⁺ 1042.2, calcd 1041.18) [M -H]^" 1040.3, calcd 1041.18); 1H NMR (DMSO-d6/D₂0) 8.23 (s, 1 H), 7.92 (s, 1H), 7.92 (s, 1H), 7.73-7.75 (t, 1H), 7.28-7.29 (t, 2H), 7.13-7.19 (m, 7H), 6.71-6.77 (dd, 4H), 6.21-6.23 (t, 1H),4.43- 4.49(q, 3H), 3.92-3.93 (d, 1H), 3.68-3.69 (d, 6H), 3.52-3.56 (q, 8H), 2.96-3.16 (m, 8H), 2.87 (s, 12H), 2.71(s, 11H), 2.26-2.36 (m, 1H), 2.01-2.06 (m 1H), 2.01-2.04 (t, 2H),1.80-1.82 (m 1H), 1.46-1.48 (m, 5H), 1.10-1.48 (m 23H). HPLC analysis single peak at 6.527 min (0 to 50% acetonitrile in 0.1M TEAA buffer) and purity is 97.21%

EXAMPLE 3

3'-(2-Cyanoethyl diisopropylphosphoramidite)-2^,-deoxy-5^,-0-(4,4'- dimethoxytrityl)-2-(12-(5-(l,2-dithiolan-3-yl)pentanamide)-dodecyl)-06-(2- trimethylsilylethyl)-Guanosine (1)

DMT-dithiolane coupled nucleoside 55 (2.4 g, 2.3 mmol) was dried by coevaporation with anhydrous CH₃CN (1 x 25 mL) and dried over-night on high vacuum pump then dissolved in anhydrous THF (25 mL). To this was added N, N'-diisopropylethylamine (1.2 mL, 6.9 mmol) and cooled in an ice cold water bath. After bubbling the argon for 25 min, 2-cyanoethyl N,A/ -(diisopropyl)phosphoramidochloridite (0.565 mL, 2.53 mmol) was added under complete argon atmosphere and the reaction mixture was stirred in ice-cold water bath for 1 h, whereupon it was diluted with EtOAc (100 mL). The organic phase was washed with saturated aqueous NaHC0₃ (100 mL), and saturated aqueous NaCl (100 ml). The combine aqueous phase was back-extracted with EtOAc (250 mL). The combined organic phase was evaporated to dryness, and the resulting residue was purified by silica gel column chromatography (29:70:01 Heane:EtOAc:Triethylamine, vlvlv) to afford target amidite 1 (1.5 g, 66%) as an color less oil. R_f = 0.5 (EtOAc:Hexane:Triethylamine, 70:29:01, vlvlv). MS mlz C₆₅H97N808PS₂Si ([M + H]⁺ 1242.3, calcd 1241.58). 3 IP NMR (CDC1₃) 149.527 and 149.196 ppm. HPLC analysis double peak at 14.924 and 16.271 min (0-30% acetoinitrile in 0.1M TEAA buffer) and purity is 99.33%.

Claims

is claimed is:

A nucleoside, comprising:

a guanine,

a 2'-deoxyribose,

a dithiolane derivative at N2 of the guanine; and

a phosphoramidite derivative at 3' or a solid support at 3', wherein the nucleoside is represented by Structure 1 or Structure 2

Structure 1 Structure 2

2. A nucleoside, comprising:

a pyrimidine;

a ribose; and

a dithiolane derivative at C5 of the pyrimidine,

wherein the nucleoside is represented by Structure 3 or Structure 4:

Structure 3 Structure 4

3. A nucleoside, comprising:

a purine;

a ribose; and

a dithiolane derivative at C8 of the purine,

wherein the nucleoside is represented by Structure 5 or Structure 6:

Structure 5 Structure 6

4. A nucleoside, comprising:

a pyrimidine;

a ribose; and

a dithiolane derivative at 2'-0 of the ribose,

wherein the nucleoside is represented by Structure 7 or Structure 8:

Structure 7 Structure 8

5. A nucleoside, comprising:

a purine;

a ribose; and

a dithiolane derivative at 2 Ό of the ribose,

wherein the nucleoside is represented by Structure 9 or Structure 10:

Structure 9 Structure 10

6. A nucleoside, comprising:

a pyrimidine;

a ribose;

a dithiolane derivative at C5 of the pyrimidine; and

a phosphoramidite group at 3'-0 of the ribose,

wherein the nucleoside is represented by Structure 11 or Structure 12:

Structure 11 Structure 12

7. A nucleoside, comprising:

a purine;

a ribose;

a dithiolane derivative at C8 of the purine; and

a phosphoramidite group at 3'-0 of the ribose,

wherein the nucleoside is represented by Structure 13 or Structure 14: ¾ tS

Structure 13 Structure 14

8. A nucleoside, comprising:

a pyrimidine;

a ribose;

a dithiolane derivative at 2'-0 of the ribose; and

a phosphoramidite group at 3'-0 of the ribose,

wherein the nucleoside is represented by Structure 15 or Structure 16:

Where

R = As Sz, :_¾3F <dirr«>rrs.' t fcsmami n::

Structure 15 Structure 16

9. A nucleoside, comprising:

a purine;

a ribose;

a dithiolane derivative at 2'-0 of the ribose; and

a phosphoramidite group at 3'-0 of the ribose,

wherein the nucleoside is represented by Structure 17 or Structure 18: ¾s:rs._.s£^"

Structure 17 Structure 18

10. A nucleoside, comprising:

a ribose;

a succinate group at 3'-0 of the ribose; and

a pyrimidine or a purine,

wherein the pyrimidine has a dithiolane derivative at C5 and the pyrimidine is represented by Structure 19 or Structure 20, and

the purine has a dithiolane derive at C8 and is represented by Structure 21 or Structure 22:

11. A nucleoside, comprising:

a nucleobase;

a ribose;

a dithiolane derivative at 2'-0 of the ribose; and

a succinate group at 3'-0 of the ribose,

wherein the nucleobase is a pyrimidine or a purine,

wherein the pyrimidine is represented by Structure 23 or Structure 24, and the purine is represented by Structure 25 or Structure 26:

12. A nucleoside, comprising:

a nucleobase;

a ribose;

a dithiolane derivative at 2'-0 of the ribose; and

a solid support at 3Ό- of the ribose,

wherein the nucleobase is a pyrimidine or a purine,

wherein the pyrimidine is represented by Structure 27 or Structure 28, and the purine is represented by Structure 29 or Structure 30:

13. A nucleoside, comprising a dithiolane derivative according to claims 1 to 12, wherein the nucleoside is represented by one of Structure 1 through Structure 30.

14. A conjugate, comprising: the nucleoside of clam 13, and a solid support,

wherein the solid support is gold or quantum, and

the conjugate is presented by the figure below: